Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             375 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 CN3: COST-EFFECTIVENESS ANALYSIS OF IRINOTECAN+5FU/FA ALONE AS FIRST-LINE THERAPY IN ADVANCED COLORECTAL CANCER IN THE UK Brown, R
 2001
 4 2 p. 54-
1 p.
 artikel
2 CN4: ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER CISPLATIN BASED TREATMENTS FOR NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK Botwood, N
 2001
 4 2 p. 54-55
2 p.
 artikel
3 CN2: EFFECT OF INCLUDING (VERSUS EXCLUDING) FATES WORSE THAN DEATH ON UTILITY MEASUREMENT Franic, DM
 2001
 4 2 p. 53-54
2 p.
 artikel
4 CN1: UTILITIES OF METASTATIC BREAST CANCER PATIENTS (PT) TREATED WITH TAXANES COMPARED TO UTILITIES OF ONCOLOGY NURSES (NUR) Hauser, R
 2001
 4 2 p. 53-
1 p.
 artikel
5 CV7: COST-EFFECTIVENESS OF CARDIOVASCULAR DISEASE (CVD) PREVENTION BY REDUCING POSTPRANDIAL HYPERGLYCEMIA Glick, H
 2001
 4 2 p. 57-
1 p.
 artikel
6 CV3: DO SHORT-ACTING OPIATES IN OFF-PUMP BYPASS SURGERY REDUCE LENGTH OF STAY OR TOTAL HOSPITAL COSTS? Reddy, P
 2001
 4 2 p. 55-56
2 p.
 artikel
7 CV6: ECONOMIC EVALUATION OF DALTEPARIN, ENOXAPARIN AND UNFRACTIONATED HEPARIN IN THE TREATMENT OF DEEP VEIN THROMBOSIS Risebrough, NA
 2001
 4 2 p. 57-
1 p.
 artikel
8 CV2: INDIRECT COMPARISONS OF DRUGS USING META-ANALYSIS: VALIDATION OF RESULTS Ross, SD
 2001
 4 2 p. 55-
1 p.
 artikel
9 CV5: THE COST-EFFECTIVENESS OF LIFETIME FACTOR VIII PROPHYLAXIS IN THE TREATMENT OF SEVERE HEMOPHILIA A Charles, RA
 2001
 4 2 p. 56-57
2 p.
 artikel
10 CV1: THE VALUE OF COMPLIANCE: EVIDENCE FROM TWO PATIENT COHORTS McGuigan, KA
 2001
 4 2 p. 55-
1 p.
 artikel
11 CV4: USING UK OBSERVATIONAL DATA TO IDENTIFY POSSIBILITIES FOR THE COST-EFFECTIVE IMPROVEMENT OF THE TREATMENT OF ATRIAL FIBRILLATION Piercy, J
 2001
 4 2 p. 56-
1 p.
 artikel
12 CV8: WORK-RELATED OUTCOMES OF PATIENTS SIX MONTHS AFTER MYOCARDIAL INFARCTION Erickson, SR
 2001
 4 2 p. 57-58
2 p.
 artikel
13 DG3: A RETROSPECTIVE EVALUATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED GASTROINTESTINAL COMPLICATIONS AMONG ADULTS IN A MANAGED CARE HEALTH PLAN Dodd, MA
 2001
 4 2 p. 59-
1 p.
 artikel
14 DG4: DISEASE SEVERITY DETERMINES COST OF GASTROESOPHAGEAL REFLUX DISEASE IN A MIDWEST USA HEALTH CARE PLAN Brelje, T
 2001
 4 2 p. 59-
1 p.
 artikel
15 DG2: THE INCREMENTAL COST OF DIABETES IN CHRONIC ILLNESS CO-OCCURRENCES Garis, RI
 2001
 4 2 p. 58-59
2 p.
 artikel
16 DG1: THE RELATIONSHIP OF DIABETES SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE Pfalzgraf, AR
 2001
 4 2 p. 58-
1 p.
 artikel
17 EM4: CAN UNIT COSTS BE COMPARED ACROSS WESTERN EUROPEAN COUNTRIES? Brown, R
 2001
 4 2 p. 48-
1 p.
 artikel
18 EM3: RESPONSE BIAS AMONG LIKELY CLINICAL TRIAL PARTICIPANTS McDonnell, DD
 2001
 4 2 p. 48-
1 p.
 artikel
19 EM1: RISK ATTITUDE: ASSOCIATION WITH MAGNITUDE OF RISK AND PATIENT CHARACTERISTICS Singer, ME
 2001
 4 2 p. 47-
1 p.
 artikel
20 EM2: THE IMPACT OF HOSPITAL COSTING METHODS ON STATISTICAL POWER IN MULTINATIONAL CLINICAL TRIALS Reed, SD
 2001
 4 2 p. 47-
1 p.
 artikel
21 HP4: ASSESSING LIFESTYLE DRUGS FOR DRUG BENEFIT FORMULARIES: A COST-UTILITY ANALYSIS OF ORLISTAT AND SIBUTRAMINE FOR THE TREATMENT OF OBESITY IN ADULTS Trakas, K
 2001
 4 2 p. 53-
1 p.
 artikel
22 HP1: ETHNIC DISPARITY OF COMBINATION RIBAVIRIN/INTERFERON ALFA-2B PRESCRIBING AMONG HEPATITIS C-INFECTED MEMBERS IN A MANAGED CARE ORGANIZATION (MCO) Phillips, AL
 2001
 4 2 p. 51-52
2 p.
 artikel
23 HP3: INCORPORATING CLINICAL OUTCOMES AND ECONOMIC CONSEQUENCES INTO DRUG FORMULARY DECISIONS: EVALUATION OF 30 MONTHS OF EXPERIENCE Atherly, DE
 2001
 4 2 p. 52-53
2 p.
 artikel
24 HP2: THE ROLE OF OUTLIER PAYMENTS IN MEDICARE PATIENTS WITH SEVERE SEPSIS Cooper, LM
 2001
 4 2 p. 52-
1 p.
 artikel
25 ID3: COST-EFFECTIVENESS ANALYSIS OF AN INTRANASAL INFLUENZA VACCINE FOR HEALTHY CHILDREN Luce, B
 2001
 4 2 p. 60-61
2 p.
 artikel
26 ID1: DEVELOPMENT OF A STOCHASTIC DECISION ANALYSIS MODEL OF TREATMENT OF PYELONEPHRITIS FROM THE RESULTS OF AN RCT Davey, P
 2001
 4 2 p. 59-60
2 p.
 artikel
27 ID2: HEALTH VALUES FOR THE LIPODYSTROPHY SYNDROME Lenert, LA
 2001
 4 2 p. 60-
1 p.
 artikel
28 ID4: THE CONFUSION BETWEEN SEPTICEMIA AND SEVERE SEPSIS Linde-Zwirble, WT
 2001
 4 2 p. 61-
1 p.
 artikel
29 MD2: ANALYSIS OF THE IMPACT OF ASSISTIVE LIVING DEVICES ON SELF-ASSESSED HEALTH STATUS RATING Rodney, AB
 2001
 4 2 p. 49-
1 p.
 artikel
30 MD1: COST-EFFECTIVENESS OF AIRLINE DEFIBRILLATORS: IS PEACE OF MIND MORE IMPORTANT THAN SAVING LIVES? Cram, P
 2001
 4 2 p. 48-49
2 p.
 artikel
31 MD4: INCLUSION OF INDIRECT COST IN ECONOMIC OUTCOMES ANALYSES OF MEDICAL DEVICES: HOW IMPORTANT IS IT? Subramanian, S
 2001
 4 2 p. 49-50
2 p.
 artikel
32 MD3: THE DIAGNOSTIC ACCURACY OF 18FDG-PET IN PATIENTS WITH RECURRENT PAPILLARY OR FOLLICULAR THYROID CANCER: A SYSTEMATIC REVIEW Hooft, L
 2001
 4 2 p. 49-
1 p.
 artikel
33 MH4: APPLICATION OF THE RASCH MODEL TO THE SF36 MENTAL HEALTH 5 ITEM SCALE (MH5) Perneger, TV
 2001
 4 2 p. 62-63
2 p.
 artikel
34 MH3: CLINICAL ASSESSMENT OF QUALITY OF LIFE AMONG SCHIZOPHRENIA PATIENTS WITH DEFICIT SYNDROME Russo, P
 2001
 4 2 p. 62-
1 p.
 artikel
35 MH2: FUTURE EMPLOYABILITY: A NEW APPROACH TO COST-EFFECTIVENESS ANALYSIS OF ANTIPSYCHOTIC THERAPY Ganguly, R
 2001
 4 2 p. 61-62
2 p.
 artikel
36 MH1: THE IMPACT OF SECOND-GENERATION ANTIPSYCHOTIC MEDICATIONS ON AMBULATORY PATIENTS WITH SCHIZOPHRENIA Mulani, PM
 2001
 4 2 p. 61-
1 p.
 artikel
37 MS4: A SYSTEMATIC REVIEW OF HEALTH STATE VALUES FOR OSTEOPOROSIS RELATED CONDITIONS Brazier, JE
 2001
 4 2 p. 64-
1 p.
 artikel
38 MS3: CORRELATION OF A GENERIC HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE AND SELF-ADMINISTERED RHEUMATOID ARTHRITIS DISEASE ACTIVITY INSTRUMENT Kim, SS
 2001
 4 2 p. 63-64
2 p.
 artikel
39 MS1: COST-EFFECTIVENESS OF INTERVENTIONS FOR LATERAL EPICONDYLITIS: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL IN PRIMARY CARE Korthals-de Bos, IBC
 2001
 4 2 p. 63-
1 p.
 artikel
40 MS2: RESPONSIVENESS TO CHANGE OF THE SF-36 IN RAPOLO, A LONGITUDINAL STUDY OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ETANERCEPT Lubeck, DP
 2001
 4 2 p. 63-
1 p.
 artikel
41 PAM13: A COST-EFFECTIVENESS MODEL COMPARING CELECOXIB AND ROFECOXIB TO TRADITIONAL NSAIDS FOR OSTEOARTHRITIS TREATMENT Schaefer, MG
 2001
 4 2 p. 70-71
2 p.
 artikel
42 PAM2: AN ECONOMIC EVALUATION OF OSTEOPOROSIS MEDICATION USE PATTERNS IN A MANAGED CARE ORGANIZATION: A TIME TO FRACTURE ANALYSIS Chen, KS
 2001
 4 2 p. 66-67
2 p.
 artikel
43 PAM11: APPLYING BACKGROUND RISK DISTRIBUTION TO EVALUATE THE COST-EFFECTIVENESS OF THREE PREVENTIVE DRUG THERAPIES FOR OSTEOPOROTIC FRACTURES Gao, X
 2001
 4 2 p. 70-
1 p.
 artikel
44 PAM19: A REVIEW OF FUNCTIONAL STATUS MEASURES FOR WORKERS WITH UPPER EXTREMITY DISORDERS Salerno, DF
 2001
 4 2 p. 73-
1 p.
 artikel
45 PAM8: COST COMPARISON OF TREATING OSTEOPOROSIS PATIENTS WITH ESTROGENS OR SELECTIVE ESTROGEN RECEPTOR MODULATOR IN A MANAGED CARE POPULATION Liao, E
 2001
 4 2 p. 68-69
2 p.
 artikel
46 PAM9: COST COMPARISON OF TREATING RHEUMATOID ARTHRITIS PATIENTS WITH COX-2 INHIBITORS OR NSAIDS IN A MANAGED CARE POPULATION Liao, E
 2001
 4 2 p. 69-
1 p.
 artikel
47 PAM20: COST-EFFECTIVENESS OF ACETYLCISTEINE AND DIMETHYLSULPHOXIDE (DMSO) 50% FOR THE TREATMENT OF PATIENTS WITH REFLEX SYMPATHIC DYSTROPHY van Dieten, HEM
 2001
 4 2 p. 73-
1 p.
 artikel
48 PAM6: COST-EFFECTIVENESS OF ROFECOXIB VERSUS NSAIDS IN THE TREATMENT OF OSTEOARTHRITIS Sullivan, P
 2001
 4 2 p. 68-
1 p.
 artikel
49 PAM16: COST IMPACT OF COX-2 INHIBITORS IN A MANAGED CARE PLAN: IMPLICATIONS FOR FORMULARY DECISION-MAKING Atherly, DE
 2001
 4 2 p. 71-72
2 p.
 artikel
50 PAM12: COST-MINIMIZATION ANALYSIS OF THE TREATMENT OF RHEUMATOID ARTHRITIS WITH LEFLUNOMIDE IN COMPARISON WITH THE COMBINATION OF INFLIXIMAB AND METHOTREXATE Rubio-Terrés, C
 2001
 4 2 p. 70-
1 p.
 artikel
51 PAM15: EVALUATING DIRECT AND INDIRECT MEASURES OF UTILITY: STABILITY OF THE SF-6D IN A RHEUMATOID ARTHRITIS POPULATION Crawford, B
 2001
 4 2 p. 71-
1 p.
 artikel
52 PAM17: IMPORTANT ISSUES IN NUMBER NEEDED TO TREAT ANALYSIS IN OSTEOPOROSIS TREATMENT Kemner, JE
 2001
 4 2 p. 72-
1 p.
 artikel
53 PAM5: INVESTIGATING THE CONSTRUCT VALIDITY OF A DISEASE SPECIFIC AND A GENERAL QUALITY OF LIFE INSTRUMENTS OF PATIENTS WITH RHEUMATOID ARTHRITIS Lovas, K
 2001
 4 2 p. 67-68
2 p.
 artikel
54 PAM1: JOINT COUNTS IN PATIENTS WITH NEW ONSET RHEUMATOID ARTHRITIS: PATIENT VS. PHYSICIAN ASSESSMENT Kim, SS
 2001
 4 2 p. 66-
1 p.
 artikel
55 PAM21: MANUAL THERAPY IS MORE COST-EFFECTIVE THAN PHYSICAL THERAPY AND GP CARE FOR PATIENTS WITH NECK PAIN IBC, Korthals-de Bos
 2001
 4 2 p. 73-74
2 p.
 artikel
56 PAM18: PERFORMANCE ASSESSMENT OF TWO FATIGUE INSTRUMENTS IN AN EARLY RHEUMATOID ARTHRITIS COHORT Drabinski, A
 2001
 4 2 p. 72-73
2 p.
 artikel
57 PAM22: STUDYING PREDICTORS OF FRACTURES AMONG OMNICARE NURSING HOME RESIDENTS Oderda, GM
 2001
 4 2 p. 74-
1 p.
 artikel
58 PAM7: THE CORRELATION BETWEEN ARTHRITIS SPECIFIC MEASURES AND SF-36 SCALES IN RHEUMATOID ARTHRITIS PATIENTS Lubeck, DP
 2001
 4 2 p. 68-
1 p.
 artikel
59 PAM3: THE COST OF OSTEOPOROTIC FRACTURES IN THE UNITED KINGDOM Burge, RT
 2001
 4 2 p. 67-
1 p.
 artikel
60 PAM10: THE IMPACT OF EARLY RHEUMATOID ARTHRITIS ON PRODUCTIVITY Kim, SS
 2001
 4 2 p. 69-
1 p.
 artikel
61 PAM14: TREATMENT WITH LEFLUNOMIDE IMPROVES THE UTILITY OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: AN APPLICATION OF THE SF-6D Crawford, B
 2001
 4 2 p. 71-
1 p.
 artikel
62 PAM4: USE OF COX 2 NSAIDS IN SUBJECTS WITHOUT RISK OF GASTROINTESTINAL SIDE EFFECTS Harley, CR
 2001
 4 2 p. 67-
1 p.
 artikel
63 PAM23: VERTEBRAL FRACTURES AMONG GLUCOCORTICOID PATIENTS SIGNIFICANTLY INCREASE MEDICAL CARE COSTS Meyer, JW
 2001
 4 2 p. 74-75
2 p.
 artikel
64 PAR8: A COST-EFFECTIVENESS ANALYSIS COMPARING LEVALBUTEROL AND ALBUTEROL IN THE TREATMENT OF MODERATE TO SEVERE ASTHMA Carter, CT
 2001
 4 2 p. 77-78
2 p.
 artikel
65 PAR14: ASSESSMENT OF THE RELATIONSHIP BETWEEN DISEASE SEVERITY, QUALITY OF LIFE AND WILLINGNESS TO PAY IN ASTHMA Zillich, A
 2001
 4 2 p. 80-
1 p.
 artikel
66 PAR15: COMPARISON OF HEALTH CARE RESOURCE UTILIZATION OF COPD PATIENTS ON CILOMILAST, 15 MG BID VERSUS PLACEBO Bagchi, I
 2001
 4 2 p. 80-
1 p.
 artikel
67 PAR4: COMPARISON OF TWO QUALITY OF LIFE INSTRUMENTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Aubert, RE
 2001
 4 2 p. 76-
1 p.
 artikel
68 PAR1: COST OF ASTHMA IN CHILDREN IN VLADIVOSTOK Prosekova, E
 2001
 4 2 p. 75-
1 p.
 artikel
69 PAR16: COST OF TREATING ASTHMA IN A MANAGED CARE POPULATION Armstrong, EP
 2001
 4 2 p. 80-81
2 p.
 artikel
70 PAR18: COSTS OF TREATING COPD IN ITALY: A BURDEN OF ILLNESS STUDY Bonzanini, A
 2001
 4 2 p. 81-
1 p.
 artikel
71 PAR23: DETERMINANTS OF INAPPROPRIATE ANTIBIOTIC PRESCRIBING Willis, MK
 2001
 4 2 p. 83-
1 p.
 artikel
72 PAR5: DIRECT AND INDIRECT COSTS OF RESPIRATORY INFECTIONS Birnbaum, HG
 2001
 4 2 p. 76-77
2 p.
 artikel
73 PAR20: EFFECTIVENESS OF COMPLIANCE ON HEALTH CARE RESOURCE USE IN ASTHMA PATIENTS TREATED WITH MONTELUKAST VS. INHALED CORTICOSTEROIDS Kutikova, L
 2001
 4 2 p. 82-
1 p.
 artikel
74 PAR13: HYPOTHETICAL VERSUS REAL WILLINGNESS TO PAY IN THE HEALTH CARE SECTOR: RESULTS FROM A FIELD EXPERIMENT Blumenschein, K
 2001
 4 2 p. 79-80
2 p.
 artikel
75 PAR22: IMPACT OF LEVALBUTEROL VERSUS RACEMIC ALBUTEROL ON OUTPATIENT ASTHMA CARE CHARGES Huse, D
 2001
 4 2 p. 83-
1 p.
 artikel
76 PAR19: IMPACT OF THE ADDITION OF SALMETEROL TO THE TREATMENT OF ASTHMA PATIENTS IN A MEDICAID FEE-FOR-SERVICE POPULATION Klaurens, LM
 2001
 4 2 p. 81-82
2 p.
 artikel
77 PAR10: IMPLEMENTING RASCH ANALYSIS IN PSYCHOMETRIC EVALUATION OF PATIENT-PHYSICIAN INTERACTION SCALE Dalal, M
 2001
 4 2 p. 78-
1 p.
 artikel
78 PAR21: LEVALBUTEROL USE IS ASSOCIATED WITH DECREASED HEALTH CARE COSTS IN PATIENTS WITH MORE SEVERE ASTHMA Huse, D
 2001
 4 2 p. 82-83
2 p.
 artikel
79 PAR17: PATIENT SATISFACTION WITH NON-SEDATING ANTIHISTAMINES Sahu, S
 2001
 4 2 p. 81-
1 p.
 artikel
80 PAR6: PROPHYLACTIC MEDICATION UTILIZATION AND HEALTH CARE COSTS IN OLDER ADULTS WITH CHRONIC PULMONARY AILMENTS Balkrishnan, R
 2001
 4 2 p. 77-
1 p.
 artikel
81 PAR12: PROSPECTIVE USE OF WEB BASED TECHNOLOGY TO EVALUATE HEALTH OUTCOMES IN A LARGE COHORT OF SEVERE OR DIFFICULT TO TREAT ASTHMATICS Dolan, CM
 2001
 4 2 p. 79-
1 p.
 artikel
82 PAR11: THE LONG-TERM SOCIETAL ECONOMIC AND HUMANISTIC BENEFITS OF TREATING ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) WITH GEMIFLOXACIN VERSUS CLARITHROMYCIN Halpern, M
 2001
 4 2 p. 78-79
2 p.
 artikel
83 PAR3: THE STANDARDIZED ASTHMA-RELATED QUALITY OF LIFE QUESTIONNAIRE (AQLQ-S): DOES SOCIOECONOMIC STATUS EFFECT MEASUREMENTS? Lynd, LD
 2001
 4 2 p. 75-76
2 p.
 artikel
84 PAR2: USE OF RESPIRATORY ASSIST DEVICES BY MEDICARE BENEFICIARIES Silverman, BG
 2001
 4 2 p. 75-
1 p.
 artikel
85 PAR7: VALIDATION OF A MODEL OF SEVERITY OF ILLNESS IN CHRONIC RESPIRATORY DISEASE Sullivan, P
 2001
 4 2 p. 77-
1 p.
 artikel
86 PAR9: VALIDATION OF A RATING INSTRUMENT ASSESSING THE INHALATION SKILLS OF CHILDREN WITH ASTHMA Pradel, FG
 2001
 4 2 p. 78-
1 p.
 artikel
87 PCN17: AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF ADVANCED COLORECTAL CANCER IN THE UK Sorensen, S
 2001
 4 2 p. 90-
1 p.
 artikel
88 PCN25: A QUALITY OF LIFE AUDIT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING CHEMOTHERAPY AT ONE INSTITUTION Musgrave, KR
 2001
 4 2 p. 93-94
2 p.
 artikel
89 PCN6: CAN ICD-9 CODES BE USED AS A PROXY FOR DISEASE STAGING IN ECONOMIC EVALUATIONS? Thomas, SK
 2001
 4 2 p. 86-
1 p.
 artikel
90 PCN1: CATEGORIZATION OF RISK OF PROSTATE CANCER: PILOT TEST OF CLINICAL OUTCOMES AND RISK PERCEPTIONS Bruner, DW
 2001
 4 2 p. 84-
1 p.
 artikel
91 PCN16: CHEMOTHERAPY TREATMENT IN NEWLY DIAGNOSED BREAST CANCER PATIENTS IN A MANAGED CARE POPULATION Yazdani, C
 2001
 4 2 p. 90-
1 p.
 artikel
92 PCN14: CHOICE OF LOCALIZED BREAST CANCER TREATMENTS IN A MEDICARE POPULATION: A COMPARISON OF OUTCOMES AND COSTS Polsky, D
 2001
 4 2 p. 89-
1 p.
 artikel
93 PCN18: COLORECTAL CANCER SCREENING: AWARENESS, UTILIZATION, AND BARRIERS Straus, W
 2001
 4 2 p. 91-
1 p.
 artikel
94 PCN19: COLORECTAL CANCER SCREENING TESTS: VARIATION IN PREFERENCES BASED ON GENDER AND RACE Straus, W
 2001
 4 2 p. 91-
1 p.
 artikel
95 PCN4: COMPARING MEAN VERSUS MEDIAN SURVIVAL AS A PRELUDE TO COST-EFFECTIVENESS (C/E) ANALYSES Gagnon, DD
 2001
 4 2 p. 85-
1 p.
 artikel
96 PCN22: COST-EFFECTIVENESS ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER Hauser, R
 2001
 4 2 p. 92-
1 p.
 artikel
97 PCN10: COST-EFFECTIVENESS MODEL OF PROSTATE-SPECIFIC ANTIGEN (PSA) SCREENING FOR PROSTATE CANCER Sokolskiy, L
 2001
 4 2 p. 87-88
2 p.
 artikel
98 PCN20: COST MINIMIZATION ANALYSIS OF CEFEPIME VERSUS IMIPENEM-CILASTATINE IN CANCER PATIENTS WITH SHORT-DURATION FEBRILE NEUTROPENIA Vorobjov, P
 2001
 4 2 p. 91-92
2 p.
 artikel
99 PCN13: COST OF THROMBOCYTOPENIA-RELATED BLEEDING AMONG PATIENTS WITH CANCER Elting, LS
 2001
 4 2 p. 88-89
2 p.
 artikel
100 PCN27: COST OF TREATMENT FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN THE UNITED STATES Cronin, K
 2001
 4 2 p. 94-95
2 p.
 artikel
101 PCN12: COST-UTILITY ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER Hauser, R
 2001
 4 2 p. 88-
1 p.
 artikel
102 PCN28: DETECTING RECURRENT PAPILLARY OR FOLLICULAR THYROID CANCER IN CLINICALPRACTICE: NEED FOR A CHANGE? Hooft, L
 2001
 4 2 p. 95-
1 p.
 artikel
103 PCN15: DIFFERENCES BETWEEN PREFERENCES FOR HEALTH STATES: THE CHEMOTHERAPY ADVERSE EVENT SELF-ASSESSED RESPONSE (CAESAR) QUESTIONNAIRE Purdum, AG
 2001
 4 2 p. 89-90
2 p.
 artikel
104 PCN23: DISEASE MODELING: DEVELOPING THE INFRASTRUCTURE FOR A COMPREHENSIVE, MULTI-NATIONAL, CLINICAL AND ECONOMIC BREAST CANCER TREATMENT MODEL Becker, RV
 2001
 4 2 p. 93-
1 p.
 artikel
105 PCN5: DOCETAXEL/DOXORRUBICIN (DD) AS FIRST LINE CHEMOTHERAPY: QUALITY OF LIFE (QOL) IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC) Bonicatto, SC
 2001
 4 2 p. 85-86
2 p.
 artikel
106 PCN7: ECONOMIC EVALUATION OF GEMZAR AND BEST SUPPORTIVE CARE (BSC) RELATIVE TO BEST SUPPORTIVE CARE ALONE IN THE TREATMENT OF NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK McKendrick, J
 2001
 4 2 p. 86-
1 p.
 artikel
107 PCN9: ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER NEW AGENTS FOR NON SMALL CELL LUNG CANCER (NSCLC) IN THE UK Lees, M
 2001
 4 2 p. 87-
1 p.
 artikel
108 PCN8: ECONOMIC EVALUATION OF GEMZAR IN THE TREATMENT OF PANCREATIC CANCER IN THE UK Stephenson, D
 2001
 4 2 p. 86-87
2 p.
 artikel
109 PCN11: ECONOMIC EVALUATION OF LIPOSOMAL DOXORUBICIN VS TOPOTECAN FOR RECURRENT OVARIAN CANCER IN THE UK Smith, DH
 2001
 4 2 p. 88-
1 p.
 artikel
110 PCN21: HEALTH-RELATED QUALITY OF LIFE AFTER ANDROGEN DEPRIVATION THERAPY IN MEN WITH PROSTATE CANCER Lubeck, DP
 2001
 4 2 p. 92-
1 p.
 artikel
111 PCN24: INCIDENCE AND COST OF HOSPITALIZATION FOR 5-FU TOXICITY AMONG MEDICARE BENEFICIARIES WITH METASTATIC COLORECTAL CANCER Delea, TE
 2001
 4 2 p. 93-
1 p.
 artikel
112 PCN3: PREDICTORS OF CHEMOTHERAPY-RELATED NEUTROPENIA: A REVIEW OF THE CLINICAL LITERATURE Palmer, C
 2001
 4 2 p. 84-85
2 p.
 artikel
113 PCN26: SYSTEMATIC ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS FOR USE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER Huang, JC
 2001
 4 2 p. 94-
1 p.
 artikel
114 PCN2: WHICH VARIABLES DO METASTATIC BREAST CANCER PATIENTS AND ONCOLOGY NURSES ANCHOR ON WHEN USING THE EUROQOL DESCRIPTIVE SYSTEM IN MEASURING UTILITIES WITH THE STANDARD GAMBLE TECHNIQUE? Hauser, R
 2001
 4 2 p. 84-
1 p.
 artikel
115 PCV1: A COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN AS PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH ESTABLISHED PERIPHERAL ARTERY DISEASE Decerbo, MC
 2001
 4 2 p. 95-
1 p.
 artikel
116 PCV3: AN ANALYSIS OF THE COST OF ADVERSE EVENTS ASSOCIATED WITH THE USE OF HMG-COA REDUCTASE INHIBITORS McBurney, CR
 2001
 4 2 p. 96-
1 p.
 artikel
117 PCV9: AN ECONOMIC ANALYSIS OF CONGESTIVE HEART FAILURE (CHF) IN THE LOUISIANA MEDICAID PROGRAM Ogale, SS
 2001
 4 2 p. 98-
1 p.
 artikel
118 PCV27: A PHARMACOECONOMIC MODEL TO EVALUATE TREATMENT OPTIONS FOR DVT PHARMACOPROPHYLAXIS Spruill, WJ
 2001
 4 2 p. 105-
1 p.
 artikel
119 PCV4: ASSESSING QUALITY OF LIFE IN PATIENTS SIX MONTHS AFTER A MYOCARDIAL INFARCTION USING THE SF-12 McBurney, CR
 2001
 4 2 p. 96-97
2 p.
 artikel
120 PCV20: ASSESSING THE TOTAL COST OF MANAGEMENT OF A PATIENT WITH DEEP VEIN THROMBOSIS (DVT) IN FRANCE AND IN ITALY Levy, E
 2001
 4 2 p. 102-103
2 p.
 artikel
121 PCV24: BEYOND THE FIRST YEAR: PATTERNS AND PREDICTORS OF LONG-TERM STATIN UTILIZATION Benner, JS
 2001
 4 2 p. 104-
1 p.
 artikel
122 PCV26: CARING FOR HYPERTENSION ON INITIATION: COSTS AND EFFECTIVENESS (CHOICE). DESIGN AND RATIONALE OF A NATURALISTIC STUDY Payne, K
 2001
 4 2 p. 105-
1 p.
 artikel
123 PCV25: CHD RISK FACTORS AND THERAPY DURATION OF HMG-COA REDUCTASE INHIBITORS (STATINS) IN A MEDICAID POPULATION Nichol, MB
 2001
 4 2 p. 104-105
2 p.
 artikel
124 PCV28: CHOLESTEROL REDUCTION SUCCESS RATES AND RESOURCE UTILIZATION BY GENDER Graff, JS
 2001
 4 2 p. 105-106
2 p.
 artikel
125 PCV31: CLOSURE OF ATRIAL SEPTAL DEFECT: MEDICO-ECONOMIC ARGUMENTS TO CHOOSE BETWEEN INVASIVE SURGERY AND PERCUTANEOUS TECHNIQUE USING SEPTAL OCCLUDER Laroche, S
 2001
 4 2 p. 107-
1 p.
 artikel
126 PCV35: COMPARABILITY OF PUBLISHED STUDIES ON COST-EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY: DO THE RESULTS HELP THE DECISION-MAKING PROCESS? Mullins, CD
 2001
 4 2 p. 108-109
2 p.
 artikel
127 PCV33: COST-ANALYSIS OF CABG SURGERY IN PATIENTS WITH AND WITHOUT RETHORACOTOMY FROM THE HOSPITAL PERSPECTIVE IN GERMANY Spannheimer, A
 2001
 4 2 p. 107-108
2 p.
 artikel
128 PCV21: COST-EFFECTIVENESS ANALYSIS OF ABCIXIMAB, EPTIFIBATIDE, AND TIROFIBAN IN PATIENTS WITH CORONARY SYNDROMES Shahriar, J
 2001
 4 2 p. 103-
1 p.
 artikel
129 PCV16: COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN VERSUS UNFRACTIONATED HEPARIN IN ACUTE CORONARY SYNDROME PATIENTS IN POLAND Orlewska, E
 2001
 4 2 p. 101-
1 p.
 artikel
130 PCV30: COST-EFFECTIVENESS MODEL OF THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION Mulani, P
 2001
 4 2 p. 106-107
2 p.
 artikel
131 PCV40: COST-EFFECTIVENESS OF LIPID LOWERING INTERVENTIONS IN A NATIVE AMERICAN CARDIOVASCULAR RISK REDUCTION PROGRAM Kumar, RN
 2001
 4 2 p. 110-111
2 p.
 artikel
132 PCV5: COST OF TREATMENT AND PREVALENCE OF CARDIOVASCULAR DISEASE COMORBIDITIES AND RISK FACTORS IN THE SEVERE AND PERSISTENTLY MENTALLY ILL Bellnier, TJ
 2001
 4 2 p. 97-
1 p.
 artikel
133 PCV39: COST OF TREATMENT OF HYPERCHOLESTEROLAEMIA TO NHF GOALS IN AUSTRALIA Wlodarczyk, J
 2001
 4 2 p. 110-
1 p.
 artikel
134 PCV11: COST OF WARFARIN TREATMENT OF ATRIAL FIBRILLATION IN CLINICAL PRACTICE Abdelhafiz, AH
 2001
 4 2 p. 99-
1 p.
 artikel
135 PCV7: COST-UTILITY ANALYSIS OF DRUG THERAPY OPTIONS FOR INTERMITTENT CLAUDICATION McGhan, WF
 2001
 4 2 p. 97-98
2 p.
 artikel
136 PCV34: DECISION ANALYSIS MODEL OF ABCIXIMAB, EPTIFIBATIDE OR STANDARD THERAPY IN ELECTIVE STENT PLACEMENT: A CANADIAN PERSPECTIVE Sridhar, K
 2001
 4 2 p. 108-
1 p.
 artikel
137 PCV19: DISCRIMINABILITY FOR RISK OF CARDIOVASCULAR EVENTS Milne, RJ
 2001
 4 2 p. 102-
1 p.
 artikel
138 PCV15: ECONOMIC EVALUATION OF OUTPATIENT ANTICOAGULANT/ANTIPLATELET THERAPY FOLLOWING CORONARY STENTING IN A MANAGED CARE POPULATION Liao, E
 2001
 4 2 p. 100-101
2 p.
 artikel
139 PCV29: ECONOMIC OUTCOMES OF PATIENTS RECEIVING CARVEDILOL COMPARED TO THOSE RECEIVING NO BETA-BLOCKER THERAPY FOR THE TREATMENT OF CONGESTIVE HEART FAILURE IN A MANAGED CARE ORGANIZATION White, TJ
 2001
 4 2 p. 106-
1 p.
 artikel
140 PCV6: ESTIMATING INCREMENTAL COSTS FOR ADDITIONAL HOSPITAL DAYS Friedman, JY
 2001
 4 2 p. 97-
1 p.
 artikel
141 PCV36: EVALUATION OF COMPLIANCE AND PERSISTENCE WITH HMG-COA REDUCTASE INHIBITORS AFTER A MYOCARDIAL INFARCTION USING PHARMACY CLAIMS DATA Coombs, JH
 2001
 4 2 p. 109-
1 p.
 artikel
142 PCV18: FRAMINGHAM RISK EQUATIONS PREDICT HOSPITAL USAGE AND MORTALITY Milne, RJ
 2001
 4 2 p. 102-
1 p.
 artikel
143 PCV14: IMPACT OF OBESITY ON HEALTH-RELATED QUALITY OF LIFE (HRQOL): AN ANALYSIS OF BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) DATA Hassan, M
 2001
 4 2 p. 100-
1 p.
 artikel
144 PCV13: IMPACT ON QUALITY ADJUSTED LIFE YEARS OF ENOXAPARIN FOR PREVENTING THROMBOSIS AMONG HOSPITALIZED MEDICAL PATIENTS Raisch, DW
 2001
 4 2 p. 100-
1 p.
 artikel
145 PCV10: INCIDENCE OF RHABDOMYOLYSIS IN PATIENTS INITIATED ON HMG CO-A REDUCTASE INHIBITOR THERAPY IN A MANAGED CARE ORGANIZATION White, TJ
 2001
 4 2 p. 98-99
2 p.
 artikel
146 PCV22: IN-PATIENT AND OUT-PATIENT RESOURCE UTILIZATION AMONG PATIENTS WITH ACUTE ISCHEMIC STROKE—THE VA EXPERIENCE L'Italien, GJ
 2001
 4 2 p. 103-
1 p.
 artikel
147 PCV8: PATIENT COMPLIANCE WITH DIFFERENT PRESCRIBED REGIMENS OF DILTIAZEM IN ANGINA PECTORIS: DATABASE ANALYSIS IN FRANCE Baptiste, C
 2001
 4 2 p. 98-
1 p.
 artikel
148 PCV42: PATIENTS' WILLINGNESS TO PAY FOR PHARMACIST MANAGED WARFARIN THERAPY AT COMMUNITY PHARMACIES Wong, PK
 2001
 4 2 p. 111-
1 p.
 artikel
149 PCV23: PHARMACOECONOMIC EVALUATION OF USAGE OF UNFRACTIONATED HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT OF DEEP VEIN THROMBOSIS IN LONG-TERM CARE RESIDENTS Karki, SD
 2001
 4 2 p. 104-
1 p.
 artikel
150 PCV12: QUALITY OF CARE IN OLDER PATIENTS ADMITTED TO HOSPITAL WITH HEART FAILURE Abdelhafiz, AH
 2001
 4 2 p. 99-100
2 p.
 artikel
151 PCV17: QUALITY OF LIFE AND PATIENT PREFERENCE AS PREDICTORS FOR RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE; INTERIM ANALYSIS Shin, GP
 2001
 4 2 p. 101-102
2 p.
 artikel
152 PCV41: SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS 1442—ONE-YEAR-RESULTS OF A PROSPECTIVE PHARMACOECONOMIC STUDY Pfeil, T
 2001
 4 2 p. 111-
1 p.
 artikel
153 PCV32: STRATEGIES FOR IMPROVING COMPLIANCE WITH HMG-COA REDUCTASE INHIBITORS Coombs, JH
 2001
 4 2 p. 107-
1 p.
 artikel
154 PCV37: THE COST-EFFECTIVENESS OF STATINS: EVIDENCE FROM THE ACCESS TRIAL Smith, DG
 2001
 4 2 p. 109-
1 p.
 artikel
155 PCV2: VENOUS THROMBOEMBOLIC (VTE) COMPLICATIONS FOLLOWING MAJOR ORTHOPEDIC SURGERY: FREQUENCY AND ECONOMIC CONSEQUENCES IN HOSPITAL Gabriel, S
 2001
 4 2 p. 95-96
2 p.
 artikel
156 PDB5: A COST-MINIMIZATION STUDY TO DETERMINE THE IMPACT OF ADDING GLUCOVANCE TO A COUNTY HOSPITAL FORMULARY Lal, LS
 2001
 4 2 p. 114-
1 p.
 artikel
157 PDB6: AN EARLY LOOK AT TZD USE AMONG TYPE 2 DIABETES PATIENTS Schabert, VF
 2001
 4 2 p. 114-
1 p.
 artikel
158 PDB16: AN OVERVIEW OF PHARMACOECONOMICS IN TURKEY: COST ANALYSIS AND REIMBURSEMENT OF ANTIDIABETIC DRUGS Sapci, AH
 2001
 4 2 p. 118-
1 p.
 artikel
159 PDB12: A PHARMACOECONOMIC ANALYSIS OF WEIGHT-REDUCTION THERAPY IN A HYPOTHETICAL COHORT OF OBESE CHINESE PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE Lee, KK
 2001
 4 2 p. 116-
1 p.
 artikel
160 PDB9: COST-EFFECTIVENESS ANALYSIS OF A MULTIDISCIPLINARY DIABETES CARE CLINIC Yokoyama, KK
 2001
 4 2 p. 115-
1 p.
 artikel
161 PDB4: COST-EFFECTIVENESS AND CARDIOVASCULAR RISK—AN ANALYSIS OF ROSIGLITAZONE COMPARED WITH OTHER ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS Oh, PI
 2001
 4 2 p. 113-
1 p.
 artikel
162 PDB7: COSTS AND EFFECTIVENESS OF INTENSIVE INSULIN THERAPY FOR TYPE 2 DIABETES Hisashige, A
 2001
 4 2 p. 114-
1 p.
 artikel
163 PDB1: DIABETIC MANAGEMENT THROUGH ORAL GLUCOSE LOWERING AGENTS: TREATMENT PATTERN, COST AND UTILIZATION ANALYSIS Thompson, FD
 2001
 4 2 p. 112-
1 p.
 artikel
164 PDB15: DOES PATIENT EXPERIENCE MATTER? TYPE II DIABETES PATIENTS' STATED PREFERENCES FOR INSULIN THERAPIES Smith, G
 2001
 4 2 p. 117-
1 p.
 artikel
165 PDB11: ECONOMIC OUTCOMES OF DIABETES AMONG AN EMPLOYED POPULATION Leong, SA
 2001
 4 2 p. 116-
1 p.
 artikel
166 PDB8: FACTORS ASSOCIATED WITH PRESCRIPTION CLAIMS FOR BLOOD GLUCOSE TEST STRIPS AMONG FEE-FOR-SERVICE NEW MEXICO MEDICAID PATIENTS Cordova, CJ
 2001
 4 2 p. 115-
1 p.
 artikel
167 PDB14: IMPACT OF A DIABETES DISEASE MANAGEMENT PROGRAM: A RETROSPECTIVE CLAIMS-BASED EVALUATION Berger, J
 2001
 4 2 p. 117-
1 p.
 artikel
168 PDB13: OPTIMIZATION OF DIABETES MANAGEMENT IN GERMANY USING A COMPUTER BASED OUTCOME PROGNOSES MODEL Brandt, A
 2001
 4 2 p. 116-117
2 p.
 artikel
169 PDB3: THE BURDEN OF ILLNESS OF DIABETES MELLITUS TYPE 2 IN GERMANY— A PILOT STUDY Tepe, M
 2001
 4 2 p. 113-
1 p.
 artikel
170 PDB10: THE COST OF NEW ONSET DIABETES MELLITUS AMONG US RENAL TRANSPLANT RECIPIENTS Woodward, RS
 2001
 4 2 p. 115-116
2 p.
 artikel
171 PDB2: USING RETROSPECTIVE CLAIMS DATA TO DESIGN CLINICAL SAFETY SURVEILLANCE OF THIAZOLIDINEDIONE DRUGS Henriques, C
 2001
 4 2 p. 112-113
2 p.
 artikel
172 PEE7: A COST COMPARISON STUDY OF COMMON PRACTICE AND BEST PRACTICE TREATMENT FOR PRIMARY OPEN-ANGLE GLAUCOMA IN THE UNITED STATES Evans, SJ
 2001
 4 2 p. 120-121
2 p.
 artikel
173 PEE1: ANTIBIOTIC PRESCRIBING PATTERNS FOR THE TREATMENT OF INITIAL ACUTE OTITIS MEDIA IN CHILDREN ENROLLED IN IOWA MEDICAID FROM 1990 THROUGH 1997 Park, TR
 2001
 4 2 p. 118-
1 p.
 artikel
174 PEE6: COST-EFFECTIVENESS OF ARTIFICIAL SKIN SUBSTITUTE VS ALLOGRAFT FOR BURN PATIENTS Bron, MS
 2001
 4 2 p. 120-
1 p.
 artikel
175 PEE3: DRY-EYE RELATED INCREASES IN HEALTH CARE UTILIZATION AND EXPENDITURES Smeeding, JE
 2001
 4 2 p. 119-
1 p.
 artikel
176 PEE8: FOUR YEAR COST-EFFECTIVENESS OF INITIAL TRABECULECTOMY VERSUS CONVENTIONAL THERAPY IN PRIMARY OPEN-ANGLE GLAUCOMA (POAG) Yu, E
 2001
 4 2 p. 121-
1 p.
 artikel
177 PEE5: INAPPROPRIATE ANTIBIOTIC PRESCRIBING AND ECONOMIC OUTCOMES FOR PEDIATRIC OTITIS MEDIA Rahman, AM
 2001
 4 2 p. 119-120
2 p.
 artikel
178 PEE2: THE COST-EFFECTIVENESS OF GENETIC TESTING FOR PERIODONTAL DISEASE. A PAYER'S PERSPECTIVE Higashi, MK
 2001
 4 2 p. 118-119
2 p.
 artikel
179 PEE4: THE FRENCH VERSION OF THE PSORIASIS DISABILITY INDEX Finlay, A
 2001
 4 2 p. 119-
1 p.
 artikel
180 PGI2: ALTERNATIVE MANAGEMENT STRATEGIES FOR DYSPEPSIA Wu, EQ
 2001
 4 2 p. 121-122
2 p.
 artikel
181 PGI16: ANALYSIS OF THE LONG-TERM COSTS, SAVINGS AND EFFECTS GENERATED BY INFLIXIMAB TO NORMALIZE QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE Annemans, L
 2001
 4 2 p. 127-
1 p.
 artikel
182 PGI3: A PROSPECTIVE, RANDOMIZED COST ANALYSIS OF MEPERIDINE AND MIDAZOLAM VERSUS PROPOFOL FOR COMPLEX UPPER ENDOSCOPY PROCEDURES Shermock, KM
 2001
 4 2 p. 122-
1 p.
 artikel
183 PGI7: BUDESONIDE CIR IS COST-EFFECTIVE IN MAINTENANCE THERAPY OF CROHN'S DISEASE IN FINLAND Ericsson, K
 2001
 4 2 p. 123-124
2 p.
 artikel
184 PGI11: CHARACTERIZATION AND MARKOV MODELING OF GASTROESOPHAGEAL REFLUX DISEASE STATES IN A LARGE HEALTH CARE PLAN Brelje, T
 2001
 4 2 p. 125-
1 p.
 artikel
185 PGI17: COMPARISON OF GENERIC VERSUS DISEASE SPECIFIC TOOLS FOR THE MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE IN CROHN'S DISEASE Wurtzbacher, JD
 2001
 4 2 p. 127-128
2 p.
 artikel
186 PGI15: COMPUTERIZED ASSESSMENT OF COMPLICATIONS FOLLOWING COLORECTAL SURGERY Kroch, E
 2001
 4 2 p. 127-
1 p.
 artikel
187 PGI6: COST-EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI ERADICATION TRIPLE THERAPY VERSUS CONVENTIONAL THERAPY FOR GASTRIC AND DUODENAL ULCERS IN JAPAN Ikeda, S
 2001
 4 2 p. 123-
1 p.
 artikel
188 PGI9: COST-EFFECTIVENESS OF ‘TEST&TREAT’ HELICOBACTER PYLORI INFECTED DYSPEPTIC PATIENTS IN A PRIMARY CARE SETTING Chen, KS
 2001
 4 2 p. 124-125
2 p.
 artikel
189 PGI1: EFFECTS ON HEALTH CARE CONTACTS AND DAYS ABSENT FROM WORK WITH BUDESONIDE CIR CAPSULES IN THE MAINTENANCE TREATMENT OF CROHN'S DISEASE IN A US SETTING Ericsson, K
 2001
 4 2 p. 121-
1 p.
 artikel
190 PGI12: ESTIMATING POTENTIAL UTILIZATION OF ESOMEPRAZOLE BY ASSESSING GERD SYMPTOM CONTROL ON TRADITIONAL PPI'S DeLattre, ML
 2001
 4 2 p. 125-126
2 p.
 artikel
191 PGI13: FACTORS ASSOCIATED WITH PHYSICIAN KNOWLEDGE OF WHETHER PRESCRIPTION DRUGS ARE ON FORMULARY Shih, YCT
 2001
 4 2 p. 126-
1 p.
 artikel
192 PGI5: HEALTH CARE COST SAVINGS WITH BUDESONIDE CONTROLLED ILEAL RELEASE CAPSULES (CIR) IN CROHN'S DISEASE Ericsson, K
 2001
 4 2 p. 123-
1 p.
 artikel
193 PGI4: HEALTH-RELATED QUALITY OF LIFE (HRQOL) DATA REVEAL DIFFERENCES AMONG CLINICAL “RESPONDERS” Watson, ME
 2001
 4 2 p. 122-123
2 p.
 artikel
194 PGI14: HOW IMPORTANT IS APPROPRIATE EMPIRICAL ANTIBIOTIC TREATMENT FOR INTRA-ABDOMINAL INFECTIONS? Davey, P
 2001
 4 2 p. 126-127
2 p.
 artikel
195 PGI10: IRRITABLE BOWEL SYNDROME COSTS SICKNESS FUNDS DM 2.8 BILLION PER YEAR Schultes, HJ
 2001
 4 2 p. 125-
1 p.
 artikel
196 PGI8: RAPID IMPACT OF RABEPRAZOLE ON SYMPTOM DISTRESS AMONG PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE Damiano, A
 2001
 4 2 p. 124-
1 p.
 artikel
197 PHP6: ACTIVITIES, FUNCTIONS AND STRUCTURE OF PHARMACY AND THERAPEUTICS COMMITTEES IN ISRAELI HOSPITALS Rotem, R
 2001
 4 2 p. 170-
1 p.
 artikel
198 PHP12: ACUTE CARE ELDERLY UNITS: THEIR PREVALENCE, CHARACTERISTICS AND DETERMINANTS Jayadevappa, R
 2001
 4 2 p. 172-173
2 p.
 artikel
199 PHP18: A MODEL FOR COMPARING COSTS ASSOCIATED WITH PRESCRIPTION WASTAGE WITH APPLICATION TO VA PRESCRIPTION DATA Walton, SM
 2001
 4 2 p. 175-
1 p.
 artikel
200 PHP7: APPLICATION OF HEALTH ECONOMICS IN THE CANADIAN PHARMACEUTICAL INDUSTRY Hirji, Z
 2001
 4 2 p. 170-171
2 p.
 artikel
201 PHP15: A SURVEY OF PUBLIC HOSPITAL PHARMACISTS IN SINGAPORE ON THEIR VIEWS ABOUT ‘THE FORMULARY’ AND ITS DECISION-MAKING PROCESS Roy, A
 2001
 4 2 p. 174-
1 p.
 artikel
202 PHP2: ATTITUDE OF PHYSICIANS TOWARD FORMULARIES AND SERVICES PROVIDED BY PHARMACIST Sansgiry, SS
 2001
 4 2 p. 168-169
2 p.
 artikel
203 PHP9: COMPARISON OF TECHNOLOGY ASSESSMENT IN LARGE MEDICAL GROUPS AND HEALTH MAINTENANCE ORGANIZATIONS (HMOS) Wise, S
 2001
 4 2 p. 171-
1 p.
 artikel
204 PHP14: COST ANALYSIS OF PHARMACEUTICAL SERVICES IN A TEACHING INSTITUTION Bussières, JF
 2001
 4 2 p. 173-
1 p.
 artikel
205 PHP4: DEVELOPING A COMPREHENSIVE PERFORMANCE MEASUREMENT DATA SET FOR PHARMACEUTICAL BENEFIT MANAGEMENT PROGRAMS Long, SR
 2001
 4 2 p. 169-170
2 p.
 artikel
206 PHP23: DRUG REIMBURSEMENT PROGRAM FOR INDIGENT PATIENTS: AN ECONOMIC IMPACT ON THE HOSPTAL ADMINISTRATION BUDGET Nguyen, AB
 2001
 4 2 p. 176-177
2 p.
 artikel
207 PHP13: INDICES FOR EVALUATION OF DRUG COST/UTILIZATION: EVERY SILVER LINING HAS A GRAY CLOUD Valuck, RJ
 2001
 4 2 p. 173-
1 p.
 artikel
208 PHP22: PATIENT ADHERENCE TO DRUG THERAPY IN A THREE-TIER COPAYMENT STRUCTURE Hutchison, S
 2001
 4 2 p. 176-
1 p.
 artikel
209 PHP17: PATIENT OUTCOMES IN THE SEDATED ICU PATIENT Kamath, T
 2001
 4 2 p. 174-175
2 p.
 artikel
210 PHP3: PHARMACOECONOMIC FELLOWSHIPS: STRUCTURE, PROCESS, AND OUTCOMES Maio, V
 2001
 4 2 p. 169-
1 p.
 artikel
211 PHP5: POLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS IN COMPARISON TO INTERNATIONAL HEALTH ECONOMIC GUIDELINES Orlewska, E
 2001
 4 2 p. 170-
1 p.
 artikel
212 PHP8: PRACTICE USE OF PHARMACOECONOMICS DATA IN HOSPITAL FORMULARY DECISIONS Odedina, FT
 2001
 4 2 p. 171-
1 p.
 artikel
213 PHP21: SINGLE EUROPEAN-LEVEL COST-EFFECTIVENESS ANALYSIS: OVER THE FOURTH HURDLE AND INTO THE DITCH? Hutton, J
 2001
 4 2 p. 176-
1 p.
 artikel
214 PHP1: THE ECONOMICS OF PARALLEL TRADE IN PHARMACEUTICALS: EXPERIENCES FROM SWEDEN Persson, UB
 2001
 4 2 p. 168-
1 p.
 artikel
215 PHP20: THE LAG BETWEEN EFFECTIVENESS AND COST-EFFECTIVENESS EVIDENCE OF NEW DRUGS AND DECISION-MAKING IN HEALTH CARE Stoykova, BA
 2001
 4 2 p. 175-176
2 p.
 artikel
216 PHP10: THE POTENTIAL BENEFITS AND DRAWBACKS OF ALLOWING DIRECT-TO-CONSUMER ADVERTISING OF PHARMACEUTICALS IN EUROPE Dickson, AJ
 2001
 4 2 p. 171-172
2 p.
 artikel
217 PHP16: THE VALUE OF VARIOUS FORMS OF EVIDENCE IN DRUG FORMULARY DECISION MAKING Morris, L
 2001
 4 2 p. 174-
1 p.
 artikel
218 PHP11: USE OF THE ANDERSEN HEALTH CARE SERVICES UTILIZATION BEHAVIORAL MODEL TO UNDERSTAND THE RELATIONSHIP BETWEEN HEALTH INSURANCE COVERAGE AND HEALTH CARE SERVICES UTILIZATION AMONG THE ELDERLY Yang, M
 2001
 4 2 p. 172-
1 p.
 artikel
219 PHP19: USING FINANCIAL RATIOS TO COMPARE PHARMACY SPENDING IN THE DEPARTMENT OF VETERANS AFFAIRS Sampson, JM
 2001
 4 2 p. 175-
1 p.
 artikel
220 PID22: AN APPRAISAL OF HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS FOR USE IN PATIENTS DIAGNOSED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE Joshi, AV
 2001
 4 2 p. 136-
1 p.
 artikel
221 PID19: AN ECONOMIC ANALYSIS OF CEFDINIR VERSUS LORACARBEF FOR TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS Shah, SN
 2001
 4 2 p. 135-
1 p.
 artikel
222 PID12: AVERTING FUTURE AIDS CASES: MODELING COSTS OF INTERVENTIONS WITH OUT-OF-TREATMENT SUBSTANCE ABUSERS Richter, A
 2001
 4 2 p. 132-133
2 p.
 artikel
223 PID28: COMPARING DIFFERENCES IN CLINICAL EFFECTIVENESS, NEPHROTOXICITY, AND COST-EFFECTIVENESS OF AMINOGLYCOSIDE THERAPY BETWEEN ALTERNATIVE DOSING PROTOCOLS Reynolds, R
 2001
 4 2 p. 138-139
2 p.
 artikel
224 PID16: COST BURDEN OF VARICELLA-ZOSTER VIRUS INFECTION IN A MANAGED CARE SETTING Schaffer, M
 2001
 4 2 p. 134-
1 p.
 artikel
225 PID24: COST COMPARISON OF GATIFLOXACIN VERSUS LEVOFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN AN OUTPATIENT POPULATION Bell, TJ
 2001
 4 2 p. 137-
1 p.
 artikel
226 PID9: COST-EFFECTIVENESS OF INTERFERON ALFA THERAPY FOR CHRONIC HEPATITIS C WITH CIRRHOSIS Hisashige, A
 2001
 4 2 p. 131-
1 p.
 artikel
227 PID8: COSTS OF HEALTH CARE FOR HEPATITIS C-INFECTED MEMBERS IN A MANAGED CARE ORGANIZATION (MCO) Schaffer, M
 2001
 4 2 p. 131-
1 p.
 artikel
228 PID27: DOES A DAY STILL MAKE A DIFFERENCE? A DECISION ANALYSIS OF ADULT STREPTOCOCCAL PHARYNGITIS Rousculp, MD
 2001
 4 2 p. 138-
1 p.
 artikel
229 PID4: ECONOMIC COST OF HIV INFECTION IN UNTREATED WORKERS: AN EMPLOYER'S PERSPECTIVE Chaikledkaew, U
 2001
 4 2 p. 129-
1 p.
 artikel
230 PID25: ECONOMIC EVALUATION OF MACROLIDES AND FLUOROQUINOLONES FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS Lachaine, J
 2001
 4 2 p. 137-138
2 p.
 artikel
231 PID17 ECONOMIC EVALUATION OF OSELTAMIVIR FOR INFLUENZA PATIENTS IN JAPAN Kobayashi, M
 2001
 4 2 p. 134-
1 p.
 artikel
232 PID13: ECONOMIC EVALUATION OF ROTAVIRUS VACCINATION FOR THE NETHERLANDS Welte, R
 2001
 4 2 p. 133-
1 p.
 artikel
233 PID10: EFFECTS OF LINEZOLID ON HOSPITAL LENGTH OF STAY IN METHICILLIN-RESISTANT STAPHYLOCOCCUS INFECTIONS ESTIMATED FROM MULTIVARIATE SURVIVAL ANALYSIS Willke, RJ
 2001
 4 2 p. 131-132
2 p.
 artikel
234 PID1: EFFICACY OF ZINC LOZENGES ON THE DURATION OF COMMON COLD SYMPTOMS: A META-ANALYSIS REVISITED Chaiyakunapruk, N
 2001
 4 2 p. 128-
1 p.
 artikel
235 PID6: HIV/AIDS HEALTH STATE UTILITIES USING COMMUNITY AND PATIENT PREFERENCE WEIGHTS: WHEN DOES IT MATTER? Schackman, BR
 2001
 4 2 p. 130-
1 p.
 artikel
236 PID2: IMPACT OF CYTOMEGALOVIRUS (CMV)-RELATED READMISSION ON POST HEART TRANSPLANT RESOURCE USE Leader, S
 2001
 4 2 p. 128-
1 p.
 artikel
237 PID15: MANAGING AIDS IN THE ERA OF ANTIRETROVIRAL THERAPY: CHANGES IN THE RATE AND COST OF HOSPITALIZATIONS O'Brien, JA
 2001
 4 2 p. 133-134
2 p.
 artikel
238 PID18: METHICILLIN-RESISTANT STAPHYLOCOCCUS SPECIES TREATMENT PATTERNS IN CANADA Becker, D
 2001
 4 2 p. 134-135
2 p.
 artikel
239 PID5: MOXIFLOXACIN VS AMOXICILLIN/CLAVULANATE IN THE TREATMENT OF ACUTE MAXILLARY SINUSITIS (AMS): EFFICACY, SAFETY AND PATIENT-REPORTED OUTCOMES IN PRIMARY CARE Rakkar, S
 2001
 4 2 p. 129-130
2 p.
 artikel
240 PID7: OBSERVATIONAL EVALUATION OF HEALTH STATE UTILITIES AMONG A COHORT OF SEPSIS PATIENTS Drabinski, A
 2001
 4 2 p. 130-
1 p.
 artikel
241 PID23: PATTERNS OF ANTIBIOTIC USE AND COSTS ASSOCIATED WITH EPISODES OF TREATMENT FOR COMMON OUTPATIENT RESPIRATORY-TRACT INFECTIONS: AN ANALYSIS OF MANAGED-CARE DATA Edelman-Lewis, B
 2001
 4 2 p. 136-137
2 p.
 artikel
242 PID11 PEGYLATED (40KDA) INTERFERON ALFA-2A (PEGASYS®) SIGNIFICANTLY IMPROVES TOLERABILITY, QUALITY OF LIFE, AND WORK PRODUCTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C Imperial, J
 2001
 4 2 p. 132-
1 p.
 artikel
243 PID26: PHARMACOECONOMIC EVALUATION OF CEFUROXIME IN ABDOMINAL HYSTERECTOMY Karpov, O
 2001
 4 2 p. 138-
1 p.
 artikel
244 PID14: PREDICTORS OF THE MENTAL (MHS) AND PHYSICAL HEALTH SUMMARY (PHS) SCORES OF THE MOS-HIV IN A SAMPLE OF HIV-INFECTED PATIENTS Griffis, DL
 2001
 4 2 p. 133-
1 p.
 artikel
245 PID20: TARGETING POPULATIONS AT-RISK FOR URINARY TRACT INFECTION COMPLICATION Doyle, B
 2001
 4 2 p. 135-
1 p.
 artikel
246 PID21: THE COST-EFFECTIVENESS ANALYSIS OF LAMIVUDINE IN THE TREATMENT OF CHRONIC HEPATITIS B IN POLAND Orlewska, E
 2001
 4 2 p. 136-
1 p.
 artikel
247 PID3: TRENDS IN INPATIENT COSTS FOR ACUTE PANCREATITIS IN THE UNITED STATES Bell, CF
 2001
 4 2 p. 129-
1 p.
 artikel
248 PMA4: AN ECONOMIC PROOF AND APPLICATION THAT FORMULARY RESTRICTIONS WITHIN DRUG CLASSES ALWAYS RESULT IN HIGHER COSTS Simons, WR
 2001
 4 2 p. 182-183
2 p.
 artikel
249 PMA5: A RISK ADJUSTMENT METHODOLOGY FOR CLAIMS DATA Wilson, P
 2001
 4 2 p. 183-
1 p.
 artikel
250 PMA14: BAYESIAN DECISION ANALYSIS IN OUTCOME STUDIES WITH SMALL NUMBERS OF EVENTS: A SIMULATION BASED PREDICTION APPROACH Wang, J
 2001
 4 2 p. 186-
1 p.
 artikel
251 PMA9: BAYESIAN OR CLASSICAL DESIGN AND ANALYSIS: DOES IT MAKE A DIFFERENCE?? Bloom, BS
 2001
 4 2 p. 184-185
2 p.
 artikel
252 PMA11: COMPARISON OF STATISTICAL TESTS FOR THE COST/EFFECTIVENESS RATIOS Kim, S
 2001
 4 2 p. 185-
1 p.
 artikel
253 PMA15: CONDUCTING PHARMACOECONOMIC RESEARCH IN THE ABSENCE OF COUNTRY-SPECIFIC DATA Miller, B
 2001
 4 2 p. 187-
1 p.
 artikel
254 PMA16: CONFIRMATION OF THE DECISION RULES AND ASSUMPTIONS FOR A MODEL OF DIABETES TREATMENT USING AN EXPERT PANEL Caro, J
 2001
 4 2 p. 187-
1 p.
 artikel
255 PMA7: CONTROLLING FOR BIASES FROM MEASUREMENT ERRORS IN HEALTH OUTCOMES RESEARCH USING STRUCTURAL EQUATION MODELING Shi, J
 2001
 4 2 p. 183-184
2 p.
 artikel
256 PMA10: DESCRIPTION OF COST/EFFECTIVENESS RATIO DISTRIBUTIONS Kim, S
 2001
 4 2 p. 185-
1 p.
 artikel
257 PMA8: DEVELOPMENT OF A CHRONIC DISEASE INDICATOR USING A MANAGED CARE POPULATION Malone, DC
 2001
 4 2 p. 184-
1 p.
 artikel
258 PMA2: DEVELOPMENT OF COST-EFFECTIVE WEB-BASED OUTCOMES RESEARCH STUDIES AND DISEASE MANAGEMENT PROGRAMS Ambegaonkar, AJ
 2001
 4 2 p. 182-
1 p.
 artikel
259 PMA3: DOES WHERE YOU LIVE AFFECT IF AND HOW YOU DISCOUNT FUTURE COSTS AND BENEFITS IN ECONOMIC EVALUATION? SHOULD IT? Faulkner, LA
 2001
 4 2 p. 182-
1 p.
 artikel
260 PMA1: METHODOLOGICAL ADVANCES IN THE ASSESSMENT OF QUALITY OF LIFE IN CLINICAL TRIALS Hufford, MR
 2001
 4 2 p. 181-
1 p.
 artikel
261 PMA12: RELATIONSHIP BETWEEN NONPARAMETRIC RECEIVER OPERATING CHARACTERISTIC ANALYSIS AND A LIKELIHOOD-RATIO TEST FOR MODEL SELECTION: I. A MONTE CARLO SIMULATION USING CONTINUOUS DATA Shaw, JW
 2001
 4 2 p. 185-186
2 p.
 artikel
262 PMA13: RELATIONSHIP BETWEEN NONPARAMETRIC RECEIVER OPERATING CHARACTERISTIC ANALYSIS AND A LIKELIHOOD-RATIO TEST FOR MODEL SELECTION: II. A MONTE CARLO SIMULATION USING DISCRETE DATA Shaw, JW
 2001
 4 2 p. 186-
1 p.
 artikel
263 PMA18: THE AVANDIA WORLDWIDE AWARENESS REGISTRY (AWARE®): AN INTERNET-BASED PROGRAM FOR EVALUATION OF CLINICAL, HUMANISTIC AND ECONOMIC OUTCOMES OF PATIENTS WITH TYPE 2 DIABETES Bakst, A
 2001
 4 2 p. 188-
1 p.
 artikel
264 PMA17: THE EUROPEAN SERVICE MAPPING SCHEDULE (ESMS): A NEW INSTRUMENT FOR MENTAL HEALTH SERVICES RESEARCH, RESULTS OF A FRENCH STUDY Azorin, JM
 2001
 4 2 p. 187-188
2 p.
 artikel
265 PMA6: THE REDUCTION OF SAMPLE SIZE FOR A COST-EFFECTIVENESS TRIAL USING A NEW METHOD: THE EIGHT CASES IN JAPAN Kamae, I
 2001
 4 2 p. 183-
1 p.
 artikel
266 PMH25: A MODEL COMPARING OLANZAPINE AND ZIPRASIDONE IN PATIENTS WITH SCHIZOPHRENIA Alexeyeva, I
 2001
 4 2 p. 148-149
2 p.
 artikel
267 PMH15: A RETROSPECTIVE ECONOMIC EVALUATION OF OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA Zhao, Z
 2001
 4 2 p. 144-145
2 p.
 artikel
268 PMH4: ASSESSMENT OF PATIENTS' ATTITUDES TOWARD ANTIPSYCHOTIC TREATMENT IN A 40-WEEK RANDOMIZED, CONTROLLED TRIAL Dugar, A
 2001
 4 2 p. 140-
1 p.
 artikel
269 PMH32: BARRIERS TO THE USE OF MEDICATIONS TO TREAT ALCOHOLISM Mark, TL
 2001
 4 2 p. 151-
1 p.
 artikel
270 PMH6: CHANGE IN INSTRUMENTAL ACTIVITIES OF DAILY LIVING ASSOCIATED WITH ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS Edell, WS
 2001
 4 2 p. 141-
1 p.
 artikel
271 PMH7: CHANGE IN MALADAPTIVE BEHAVIORS ASSOCIATED WITH ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS Jensik, SE
 2001
 4 2 p. 141-142
2 p.
 artikel
272 PMH29: COST ANALYSIS OF OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF UNCONTROLLED SCHIZOPHRENIA Zhao, Z
 2001
 4 2 p. 150-
1 p.
 artikel
273 PMH27: COST-UTILITY ANALYSIS OF QUETIAPINE COMPARED TO RISPERIDONE IN THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA OR OTHER PSYCHOTIC DISORDERS Simons, WR
 2001
 4 2 p. 149-
1 p.
 artikel
274 PMH14: DEFICIT SYNDROME AND DRUG USE PATTERNS IN COMMUNITY-BASED SCHIZOPHRENIA CARE Russo, P
 2001
 4 2 p. 144-
1 p.
 artikel
275 PMH23: DEINSTITUTIONALIZATION OF SCHIZOPHRENIC PATIENTS: COST-CONSEQUENCES AND POLICY IMPLICATION OF INTENSIVE CASE MANAGEMENT VERSUS STANDARD CASE MANAGEMENT Llorca, PM
 2001
 4 2 p. 148-
1 p.
 artikel
276 PMH28: DEPRESSION AND HOMELESSNESS, A FRENCH INITIATIVE Emmanuelli, X
 2001
 4 2 p. 149-150
2 p.
 artikel
277 PMH30: DIFFERENCES IN HEALTH CARE EXPENDITURES AMONG PATIENTS TREATED FOR DEPRESSION WITH OR WITHOUT ANXIETY Crown, W
 2001
 4 2 p. 150-
1 p.
 artikel
278 PMH36: DOSING OF BENZODIAZEPINE HYPNOTICS IN ELDERLY PATIENTS Young, JK
 2001
 4 2 p. 153-
1 p.
 artikel
279 PMH20: DOSING OF BENZODIAZEPINE HYPNOTICS IN ELDERLY PATIENTS Young, JK
 2001
 4 2 p. 146-147
2 p.
 artikel
280 PMH5: FROM FIRST TO SECOND: IMPACT OF PARTICIPANT CHARACTERISTICS ON THE TIME TO FIRST SWITCH IN A SCHIZOPHRENIA POPULATION Russo, P
 2001
 4 2 p. 140-141
2 p.
 artikel
281 PMH9: HEALTH CARE UTILIZATION AND COSTS IN SCHIZOPHRENIC PATIENTS TAKING RISPERIDONE VERSUS OLANZAPINE IN A VETERANS ADMINISTRATION POPULATION Shermock, KM
 2001
 4 2 p. 142-
1 p.
 artikel
282 PMH18 HEALTH CARE UTILIZATION IN PATIENTS WITH TREATMENT RESISTANT DEPRESSION Crown, WH
 2001
 4 2 p. 146-
1 p.
 artikel
283 PMH10: HEALTH OUTCOMES OF CHILDHOOD ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): HEALTH CARE USE AND WORK STATUS OF CAREGIVERS Noe, L
 2001
 4 2 p. 142-143
2 p.
 artikel
284 PMH8: IMPACT OF CURRENT ANTIDEPRESSANTS ON COGNITION IN OLDER PATIENTS WITH DEPRESSION Adams, BE
 2001
 4 2 p. 142-
1 p.
 artikel
285 PMH3: IS DEPRESSION THE MAJOR CAUSE OF IMPAIRED QUALITY OF LIFE IN SCHIZOPHRENIC PATIENTS? Toumi, M
 2001
 4 2 p. 140-
1 p.
 artikel
286 PMH33: OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA: A COMPARISON OF COSTS AMONG TEXAS MEDICAID PATIENTS Rascati, KL
 2001
 4 2 p. 151-152
2 p.
 artikel
287 PMH26: OUTPATIENT ANTIPSYCHOTIC USE: COMPARING ATYPICAL AND CONVENTIONAL ANTIPSYCHOTIC ADHERENCE USING A NATIONAL RETAIL PHARMACY DATA BASE Vanelli, MR
 2001
 4 2 p. 149-
1 p.
 artikel
288 PMH35: PATTERNS OF ANTIDEPRESSANT AND ANTIPSYCHOTIC MEDICATION USE IN MEDICAID, 1995-1999 Gregorian, R
 2001
 4 2 p. 152-
1 p.
 artikel
289 PMH22: PATTERNS OF ANTIDEPRESSANT USE AND HEALTH CARE COSTS IN DEPRESSED PATIENTS WHO RECEIVED SSRI THERAPY Wade, SW
 2001
 4 2 p. 147-148
2 p.
 artikel
290 PMH31: PHARMACOECONOMIC EVALUATION OF THE TREATMENT WITH OLANZAPINE IN “REVOLVING DOOR” SCHIZOPHRENIC PATIENTS Gurovich, I
 2001
 4 2 p. 151-
1 p.
 artikel
291 PMH13: PRE-TREATMENT PATIENT DIFFERENCES: CHOICE OF DRUG THERAPY WITHIN SCHIZOPHRENIA Gibson, PJ
 2001
 4 2 p. 144-
1 p.
 artikel
292 PMH12: PREVALENCE OF COMORBID ANXIETY AND DEPRESSION AMONG PATIENTS PRESCRIBED SSRI MONOTHERAPY Grotzinger, KM
 2001
 4 2 p. 143-144
2 p.
 artikel
293 PMH21: QUALITY OF LIFE OF NON-INSTITUTIONAL CAREGIVERS OF SCHIZOPHRENIC PATIENTS: CONTRIBUTION OF QUALITATIVE INTERVIEWS TO QUESTIONNAIRE GENERATION Auquier, P
 2001
 4 2 p. 147-
1 p.
 artikel
294 PMH19: RISK OF HOSPITALIZATION FOR PATIENTS WITH BIPOLAR DISORDER Ling, DCY
 2001
 4 2 p. 146-
1 p.
 artikel
295 PMH11: SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP): THE IMPACT OF CLINICAL SYNDROME, ANTIPSYCHOTIC MEDICATION TREATMENT AND ADHERENCE ON OUTPATIENT PSYCHIATRIC UTILIZATION Russo, P
 2001
 4 2 p. 143-
1 p.
 artikel
296 PMH1: SHOULD THE 51 ITEMS OF THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP-51) BE WEIGHTED? Barr, J
 2001
 4 2 p. 139-
1 p.
 artikel
297 PMH34: SWITCHING AND AUGMENTATION OF ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS Adams, BE
 2001
 4 2 p. 152-
1 p.
 artikel
298 PMH24: THE COST OF ACUTE HOSPITALIZATION FOR ANOREXIA NERVOSA AND BULIMIA O'Brien, JA
 2001
 4 2 p. 148-
1 p.
 artikel
299 PMH2: TREATMENT COURSE AND CHARGES FOR DEPRESSED PATIENTS TREATED WITH SERTRALINE, VENLAFAXINE, AND VENLAFAXINE XR IN THE MANAGED CARE SETTING Hirschfeld, R
 2001
 4 2 p. 139-140
2 p.
 artikel
300 PMH17: TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: ASSESSMENT OF CLINICAL AND ECONOMIC OUTCOMES USING A MARKOV MODEL Neeser, K
 2001
 4 2 p. 145-146
2 p.
 artikel
301 PMH16: USE OF RASCH MODELS FOR VALIDATION OF INSTRUMENTS USED IN MENTAL HEALTH EVALUATION Lançon, C
 2001
 4 2 p. 145-
1 p.
 artikel
302 PPN17: ADDRESSING PARADOXES IN ECONOMIC EVALUATIONS (EES). AN EXAMPLE USING MOTOR NEURON DISEASE (MND) Bose, UK
 2001
 4 2 p. 159-160
2 p.
 artikel
303 PPN7: A MODEL FOR PREDICTING THE INCIDENCE OF MIGRAINE IN THE IDAHO MEDICAID POPULATION Shaw, J
 2001
 4 2 p. 155-156
2 p.
 artikel
304 PPN1: AN INTERNET STUDY OF WTP FOR MIGRAINE PHARMACOTHERAPIES Lenert, LA
 2001
 4 2 p. 153-
1 p.
 artikel
305 PPN14: A PROGNOSTIC MODEL TO PREDICT QUALITY OF LIFE CHANCES AFTER SUBARACHNOID HEMORRHAGE Toth, K
 2001
 4 2 p. 158-
1 p.
 artikel
306 PPN5: COMPARISON OF COSTS AND COST-EFFECTIVENESS OF OXCARBAZEPINE AND SODIUM VALPROATE FOR NEW/RECENT ONSET PARTIAL SEIZURES Bazalo, G
 2001
 4 2 p. 155-
1 p.
 artikel
307 PPN19: COMPARISON OF HUI2 AND HUI3 SCORES FOR PATIENTS WITH ALZHEIMER'S DISEASE Niwata, S
 2001
 4 2 p. 160-
1 p.
 artikel
308 PPN18: COST SAVINGS IN MIGRAINE ASSOCIATED WITH LESS CHEST PAIN ON NEW TRIPTAN THERAPY Wang, JT
 2001
 4 2 p. 160-
1 p.
 artikel
309 PPN13: DELAYS IN NURSING HOME PLACEMENT FOR PATIENTS WITH ALZHEIMER'S DISEASE ASSOCIATED WITH TREATMENT WITH DONEPEZIL MAY HAVE HEALTH CARE COST-SAVING IMPLICATIONS Provenzano, G
 2001
 4 2 p. 158-
1 p.
 artikel
310 PPN12: DIFFERENCES IN HEALTH-RELATED QUALITY OF LIFE BETWEEN MIGRAINEURS WITH AND WITHOUT PROPHYLACTIC MEDICATION USE Girts, TK
 2001
 4 2 p. 157-158
2 p.
 artikel
311 PPN16: ECONOMIC BURDEN AND LOSS IN QUALITY OF LIFE DUE TO LOW BACK PAIN Szende, A
 2001
 4 2 p. 159-
1 p.
 artikel
312 PPN20: ESTIMATED RESOURCE USE AND COST OF MITOXANTRONE VS PLACEBO IN PATIENTS WITH PROGRESSIVE-RELAPSING AND SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS: RESULTS FROM THE MIMS TRIAL Durgin, TL
 2001
 4 2 p. 160-161
2 p.
 artikel
313 PPN9: HOW IS PAIN FELT ACROSS COUNTRIES? THE SHORT-FORM MCGILL PAIN QUESTIONNAIRE (SF-MPQ) IN 10 LANGUAGES Conway, K
 2001
 4 2 p. 156-
1 p.
 artikel
314 PPN21: MIGRAINE IN FRANCE IN 2000:THERAPEUTICAL DATA Lucas, C
 2001
 4 2 p. 161-
1 p.
 artikel
315 PPN15: MULTIPLE PAIN RELIEF ASSESSMENT IN WOMEN UNDERGOING NATURAL VERSUS EPIDURAL DELIVERY WITH ROPIVACAIN OR BUPIVACAIN Szende, A
 2001
 4 2 p. 159-
1 p.
 artikel
316 PPN8: PSYCHOMETRIC EVALUATION OF WIDELY USED PAIN MEASURES FOR PURPOSE OF COMPUTERIZED DYNAMIC PAIN ASSESSMENT Zhao, JH
 2001
 4 2 p. 156-
1 p.
 artikel
317 PPN10: SURVIVAL AND NURSING HOME FREE SURVIVAL (NHFS) OF AD PATIENTS Wu, EQ
 2001
 4 2 p. 157-
1 p.
 artikel
318 PPN3: THE IMPACT OF DEMENTIA ON CAREGIVER QUALITY OF LIFE Gold, KF
 2001
 4 2 p. 154-
1 p.
 artikel
319 PPN11: THE MIGRAINE IN FRANCE IN 2000: EPIDEMIOLOGICAL DATA Henry, P
 2001
 4 2 p. 157-
1 p.
 artikel
320 PPN2: USE OF GALANTAMINE IN THE NETHERLANDS FOR THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE Caro, J
 2001
 4 2 p. 153-154
2 p.
 artikel
321 PPN4: UTILITY ASSESSMENTS OF OPIOID TREATMENT IN THE US, CANADA AND AUSTRALIA FOR PATIENTS WITH CHRONIC NON-MALIGNANT PAIN Schmier, J
 2001
 4 2 p. 154-
1 p.
 artikel
322 PPN6: VALIDATION OF THE 24 HOUR HEADACHE DISABILITY QUESTIONNAIRE (DISQ-24) IN A SAMPLE OF HEADACHE SUFFERERS Runken, MC
 2001
 4 2 p. 155-
1 p.
 artikel
323 PQP4: CROSS-CULTURAL VARIATIONS IN SF-12 SCORES AMONG INDIVIDUALS WITH VARIOUS HEALTH CONDITIONS Bolge, SC
 2001
 4 2 p. 178-
1 p.
 artikel
324 PQP3: DEFINING CLINICALLY MEANINGFUL CHANGE IN HEALTH-RELATED QUALITY OF LIFE Crosby, RD
 2001
 4 2 p. 178-
1 p.
 artikel
325 PQP8: EVALUATING BIAS INTRODUCED BY ANNUALIZING UTILIZATION AND COST MEASURES Zodet, M
 2001
 4 2 p. 179-180
2 p.
 artikel
326 PQP6: HEALTH UTILITIES INDEX MARK 3: AGREEMENT BETWEEN RATERS AND BETWEEN MODALITIES OF ADMINISTRATION Verrips, G
 2001
 4 2 p. 179-
1 p.
 artikel
327 PQP7: IS COMPLIANCE WITH DRUG TREATMENT CORRELATED WITH HEALTH RELATED QUALITY OF LIFE? Côté, I
 2001
 4 2 p. 179-
1 p.
 artikel
328 PQP1: LESSONS LEARNED FROM DEVELOPING A PSYCHOMETRICALLY BASED SEDATION QUESTIONNAIRE IN PHARMACOLOGICALLY PARALYZED CRITICALLY ILL PATIENTS Kane, SL
 2001
 4 2 p. 177-
1 p.
 artikel
329 PQP10: NEGATIVE AFFECTIVITY: A SIGNIFICANT CONTAMINANT OF PATIENT REPORTED HEALTH RELATED QUALITY OF LIFE INSTRUMENTS (SF-36) Reed, PJ
 2001
 4 2 p. 180-181
2 p.
 artikel
330 PQP9: QUALITY OF LIFE OF PATIENTS WITH FABRY DISEASE Botteman, MF
 2001
 4 2 p. 180-
1 p.
 artikel
331 PQP2: ROLE OF HEALTH RELATED QUALITY OF LIFE OUTCOMES IN THE EUROPEAN DRUG REGULATORY PROCESS: A REVIEW OF THE EMEA DOCUMENTS Acquadro, C
 2001
 4 2 p. 177-178
2 p.
 artikel
332 PQP11: THE HEALTH AND WORK QUESTIONNAIRE (HWQ): AN INSTRUMENT FOR ASSESSING WORKPLACE PRODUCTIVITY IN RELATION TO WORKER HEALTH Shikiar, R
 2001
 4 2 p. 181-
1 p.
 artikel
333 PQP5: TRANSLATING SF-36 SCORES INTO PREFERENCES: AN EXAMINATION OF THE PERFORMANCE OF TWO PREDICTIVE EQUATIONS Meletiche, DM
 2001
 4 2 p. 178-179
2 p.
 artikel
334 PUR4: ANALYSIS OF COMORBIDITY IN OVERACTIVE BLADDER AND URINARY INCONTINENCE IN A MANAGED CARE ORGANIZATION Juzba, M
 2001
 4 2 p. 163-
1 p.
 artikel
335 PUR7: CLINICAL CORRELATES WITH HEALTH-RELATED QUALITY OF LIFE SCORES AND SUBSCALES AMONG CONSULTING AND NON-CONSULTING INDIVIDUALS WITH STRESS URINARY INCONTINENCE Rao, S
 2001
 4 2 p. 164-
1 p.
 artikel
336 PUR2: EVIDENCE OF DISEASE PROGRESSION IN ADULT PATIENTS WITH AN OVERACTIVE BLADDER (OAB) Zhou, Z
 2001
 4 2 p. 162-
1 p.
 artikel
337 PUR1: HEALTH STATUS OF ELDERLY DIALYSIS PATIENTS Boening, AJ
 2001
 4 2 p. 162-
1 p.
 artikel
338 PUR3: PERSISTENCE OF THERAPY WITH DRUGS FOR OVERACTIVE BLADDER Zhou, Z
 2001
 4 2 p. 162-163
2 p.
 artikel
339 PUR5: THE IMPACT OF PHARMACOTHERAPY ON OVERACTIVE BLADDER SYMPTOM IMPROVEMENT AND RESOURCE UTILIZATION Pashos, CL
 2001
 4 2 p. 163-164
2 p.
 artikel
340 PUR8: THE INFLUENCE OF RACE ON SF-36 SCORES OF DIALYSIS PATIENTS Boening, AJ
 2001
 4 2 p. 164-165
2 p.
 artikel
341 PUR6: THE RELIABILITY AND VALIDITY OF A NEW OAB-SPECIFIC HRQL QUESTIONNAIRE (OAB-Q) Coyne, K
 2001
 4 2 p. 164-
1 p.
 artikel
342 PWM2: A COST-MINIMIZATION ANALYSIS COMPARING MIRENA® WITH ORAL CONTRACEPTIVES Menard, G
 2001
 4 2 p. 165-166
2 p.
 artikel
343 PWM6: COST-EFFECTIVENESS OF INTRAVAGINAL PROSTAGLANDIN E2 GEL AND INTRAVAGINAL MISOPROSTOL FOR PREINDUCTION CERVICAL RIPENING Gagne, AL
 2001
 4 2 p. 167-
1 p.
 artikel
344 PWM3: ERECTILE DYSFUNCTION: A PROSPECTIVE STUDY OF PATIENTS SEEKING THERAPY Jackson-Kline, SE
 2001
 4 2 p. 166-
1 p.
 artikel
345 PWM5: HEALTH CARE USE ATTRIBUTABLE TO PROSTATE NON-SELECTIVE ALPHA-1 ANTAGONIST INITIATION FOR BENIGN PROSTATIC HYPERPLASIA (BPH) Chrischilles, EA
 2001
 4 2 p. 167-
1 p.
 artikel
346 PWM4: PHARMACIST-INITIATED EMERGENCY CONTRACEPTION IN BRITISH COLUMBIA Fielding, D
 2001
 4 2 p. 166-
1 p.
 artikel
347 PWM1: PREMATURE BIRTH AND RESOURCE UTILIZATION IN A LARGE EMPLOYMENT BASED INDEPENDENT PRACTICE ASSOCIATION (IPA) Harley, CR
 2001
 4 2 p. 165-
1 p.
 artikel
348 PWM8: QUALITY OF LIFE IN POST-MENOPAUSAL WOMEN IN FIVE EUROPEAN COUNTRIES Piercy, J
 2001
 4 2 p. 168-
1 p.
 artikel
349 PWM7: THE EFFECT AND ECONOMIC IMPACT OF STANDARDIZED ORDERS ON THE PREVENTION AND TREATMENT OF PONV IN HOSPITALIZED GYNECOLOGICAL SURGERY PATIENTS Marra, C
 2001
 4 2 p. 167-168
2 p.
 artikel
350 QL1: DOES SOCIOECONOMIC STATUS AFFECT THE VALUATION OF HEALTH? Asada, Y
 2001
 4 2 p. 50-
1 p.
 artikel
351 QL2: LOGICAL CONSISTENCY AND THE VALUATION OF HEALTH: AN ANALYSIS OF US SURVEY DATA Craig, BM
 2001
 4 2 p. 50-51
2 p.
 artikel
352 QL3: QUALITY OF LIFE IN PRODUCT LABELING: A REVIEW OF MARKETED DRUG PRODUCTS Chopra, T
 2001
 4 2 p. 51-
1 p.
 artikel
353 QL4: QUALITY OF LIFE MESSAGES IN PRESCRIPTION DRUG ADVERTISEMENTS IN LEADING MEDICAL JOURNALS, 1990-99 Zivin, K
 2001
 4 2 p. 51-
1 p.
 artikel
354 RS4: A MODEL-BASED EVALUATION OF INHALED STEROIDS IN MILD-TO-MODERATE ASTHMA Paltiel, A
 2001
 4 2 p. 65-66
2 p.
 artikel
355 RS1: OUTCOME ASSESSMENT IN PEDIATRIC ASTHMA: A COMPARISON OF SYMPTOM-FREE TIME AND MULTI-ATTRIBUTE SCALE Chiou, CF
 2001
 4 2 p. 64-65
2 p.
 artikel
356 RS3: PSYCHOMETRIC EVALUATION OF THE CAP-SYM QUESTIONNAIRE: A NEW, PATIENT-BASED MEASURE OF SYMPTOMS IN COMMUNITY ACQUIRED PNEUMONIA Lamping, D
 2001
 4 2 p. 65-
1 p.
 artikel
357 RS2: USING SELF-ADMINISTERED DIRECT TTO QUESTIONS TO ELICIT UTILITY VALUES FOR ASTHMATIC PATIENTS WITH DIFFERENT SEVERITY OF DISEASE Szende, A
 2001
 4 2 p. 65-
1 p.
 artikel
358 WW4: A NEW APPROACH TO DISEASE MODELING WITH NUMEROUS COMPARATORS AND MULTIPLE DECISION TREES Becker, R
 2001
 4 2 p. 189-190
2 p.
 artikel
359 WW7: BEYOND COST-EFFECTIVENESS: THE STRATEGIC VALUE OF PRODUCTIVITY-RELATED OUTCOMES IN CLINICAL TRIALS, BURDEN OF ILLNESS STUDIES, AND POST-MARKETING RESEARCH Ozminkowski, RJ
 2001
 4 2 p. 191-
1 p.
 artikel
360 WW13: CHALLENGES IN PERFORMING META ANALYSIS IN HEART FAILURE OUTCOMES RESEARCH Mullins, CD
 2001
 4 2 p. 193-
1 p.
 artikel
361 WW6: CONDUCTING COST-BENEFIT AND COST-UTILITY ANALYSES: A CONJOINT ANALYSIS APPROACH Hauber, AB
 2001
 4 2 p. 190-191
2 p.
 artikel
362 WW8: CONSTRUCTING EPISODES OF CARE FROM CLAIMS DATA: APPLICATIONS TO PHARMACOECONOMIC AND OUTCOMES RESEARCH Huse, D
 2001
 4 2 p. 191-
1 p.
 artikel
363 WW5: CREATIVE APPROACHES TO MODELING LIFE EXPECTANCY GAINS FOR ECONOMIC EVALUATION USING PUBLISHED DATA Weinstein, MC
 2001
 4 2 p. 190-
1 p.
 artikel
364 WW15: IDENTIFYING THE IMPACT OF A TREATMENT ON OUTCOMES AND COSTS USING OBSERVATIONAL DATA: OVERCOMING SELECTION BIAS Polsky, D
 2001
 4 2 p. 194-
1 p.
 artikel
365 WW3: ISSUES AND PROBLEMS ENCOUNTERED IN MODELS ON PREVENTION OF DEEP VENOUS THROMBOSIS (DVT) Annemans, L
 2001
 4 2 p. 189-
1 p.
 artikel
366 WW14: MAKING MODELS BETTER Matchar, DB
 2001
 4 2 p. 193-194
2 p.
 artikel
367 WW1: METHODOLOGICAL COMPLEXITIES IN USING ADMINISTRATIVE CLAIMS DATABASES TO EVALUATE QUALITY OF CARE FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER Hankin, CS
 2001
 4 2 p. 188-189
2 p.
 artikel
368 WW10: MULTINATIONAL ECONOMIC STUDIES: LESSONS LEARNED FROM TRIAL-BASED AND MODELLING STUDIES Drummond, MF
 2001
 4 2 p. 192-
1 p.
 artikel
369 WW16: PATIENT REGISTRIES: THEIR VALUE IN OUTCOMES RESEARCH Russell, MW
 2001
 4 2 p. 194-195
2 p.
 artikel
370 WW17: SELECTING HEALTH-RELATED QUALITY-OF-LIFE MEASURES: FIRST PRINCIPLES Erickson, P
 2001
 4 2 p. 195-
1 p.
 artikel
371 WW18: THE ROLE OF HEALTH STATE EXPERIENCE IN LONGITUDINAL CONJOINT ANALYSIS OF PATIENT PREFERENCES Bingham, M
 2001
 4 2 p. 195-
1 p.
 artikel
372 WW9: THE USE OF MULTI-ATTRIBUTE ANALYSIS AND PAIR-WISE COMPARISONS FOR GROUP DECISION-MAKING Hess, GP
 2001
 4 2 p. 192-
1 p.
 artikel
373 WW12: USE OF MEDICATION COMPLIANCE DATA IN OUTCOME ANALYSES Cramer, JA
 2001
 4 2 p. 193-
1 p.
 artikel
374 WW2: USING LINKABLE CLINICAL AND ADMINISTRATIVE CLAIMS DATA TO IMPROVE OUTCOMES RESEARCH: SELECTED CASE STUDIES FROM ONCOLOGY AND DIABETES MELLITUS Menzin, J
 2001
 4 2 p. 189-
1 p.
 artikel
375 WW11: USING MARKOV DECISION MODELS TO DEVELOP OPTIMAL TREATMENT PATHWAYS: AN ILLUSTRATION Bala, MV
 2001
 4 2 p. 192-193
2 p.
 artikel
                             375 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland